NCCN presented new updates to the NCCN Clinical Practice Guidelines in Oncology(TM) for Thyroid Carcinoma at the NCCN 14th Annual Conference on March 14. Notable updates include a new page on Thyroid Stimulating Hormone (TSH) Suppression, the expanded recommendation of small molecule kinase inhibitors, and revised procedures for evaluating thyroid nodules. Steven I. Sherman, MD, of The
HOLLYWOOD, Fla., March 16 /PRNewswire-USNewswire/ -- The incidence of thyroid carcinoma is increasing faster than any other solid tumor according to Steven I. Sherman, MD, of The
"The increasing incidence of thyroid carcinoma is a worldwide phenomenon," stated Dr. Sherman as he outlined major updates to the NCCN Guidelines.
A notable addition to the NCCN Guidelines is a recommendation to consider commercially available, small molecule kinase inhibitors such as sorafenib (Nexavar(R), Bayer) or sunitinib (Sutent(R), Pfizer, Inc.) in the treatment of metastatic papillary carcinoma, follicular carcinoma, Hurthle cell carcinoma, or medullary carcinoma.
"Our primary recommendation for these patients is to investigate a clinical trial, but if one is not available or appropriate; data from clinical trials have shown that small molecule kinase inhibitors such as sorafenib and sunitinib can be effective," said Dr. Sherman.
Also new to the NCCN Guidelines is a page, Principles of Thyroid Stimulating Hormone (TSH) Suppression that provides recommendations for levothyroxine use for TSH Suppression th
|SOURCE National Comprehensive Cancer Network|
Copyright©2009 PR Newswire.
All rights reserved